Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sonja Molin

Showing results (51-60 of 61) with videos related to

Pageof 7
Sort By:
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2025
Dupilumab improves quality of life assessed by the Quality of Life in Hand Eczema QuestionnaireEric L Simpson, Marie-Louise A Schuttelaar, Sonja Molin, et al.
Journal of the American Academy of Dermatology|August 24, 2024
Prevalence and clinical impact of topical corticosteroid phobia among patients with chronic hand eczema-Findings from the Danish Skin CohortMaria O Christensen, Johan Sieborg, Lea K Nymand, et al.
Allergy|April 17, 2020
TCRs with segment TRAV9-2 or a CDR3 histidine are overrepresented among nickel-specific CD4+ T cellsMarina Aparicio-Soto, Franziska Riedel, Melanie Leddermann, et al.
The Lancet. Child & Adolescent Health|June 3, 2026
Delgocitinib cream for adolescents with moderate to severe chronic hand eczema (DELTA TEEN): a multicentre, double-blind, phase 3 randomised controlled trialSonja Molin, Eulalia Baselga, Francisco J Navarro-Triviño, et al.
Journal of the American Academy of Dermatology|March 13, 2025
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trialsMelinda Gooderham, Sonja Molin, Robert Bissonnette, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 13, 2023
S2k-Leitlinie Diagnostik, Prävention und Therapie des Handekzems: S2k guideline diagnosis, prevention and therapy of hand eczemaAndrea Bauer, Richard Brans, Randolf Brehler, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 13, 2023
S2k guideline diagnosis, prevention, and therapy of hand eczemaAndrea Bauer, Richard Brans, Randolf Brehler, et al.
Contact Dermatitis|May 13, 2017
Current knowledge on biomarkers for contact sensitization and allergic contact dermatitisSjors A Koppes, Kristiane A Engebretsen, Tove Agner, et al.
Contact Dermatitis|July 1, 2016
A variant of the CXCL11 gene may influence susceptibility to contact allergy, particularly in polysensitized patientsGötz A Westphal, Hans-Peter Rihs, Antje Schaffranek, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 25, 2025
Consensus on core domains for hand eczema trials: Signs, symptoms, control and quality of lifeHenriette Rönsch, Karl Philipp Drewitz, Amber Reck Atwater, et al.
Pageof 7

Showing results (51-60 of 61) with videos related to

Sort By:
Pageof 7
Journal of the European Academy of Dermatology and Venereology : JEADV|October 4, 2025
Dupilumab improves quality of life assessed by the Quality of Life in Hand Eczema QuestionnaireEric L Simpson, Marie-Louise A Schuttelaar, Sonja Molin, et al.
Journal of the American Academy of Dermatology|August 24, 2024
Prevalence and clinical impact of topical corticosteroid phobia among patients with chronic hand eczema-Findings from the Danish Skin CohortMaria O Christensen, Johan Sieborg, Lea K Nymand, et al.
Allergy|April 17, 2020
TCRs with segment TRAV9-2 or a CDR3 histidine are overrepresented among nickel-specific CD4+ T cellsMarina Aparicio-Soto, Franziska Riedel, Melanie Leddermann, et al.
The Lancet. Child & Adolescent Health|June 3, 2026
Delgocitinib cream for adolescents with moderate to severe chronic hand eczema (DELTA TEEN): a multicentre, double-blind, phase 3 randomised controlled trialSonja Molin, Eulalia Baselga, Francisco J Navarro-Triviño, et al.
Journal of the American Academy of Dermatology|March 13, 2025
Long-term safety and efficacy of delgocitinib cream for up to 52 weeks in adults with Chronic Hand Eczema: Results of the phase 3 open-label extension DELTA 3 trial following the DELTA 1 and 2 trialsMelinda Gooderham, Sonja Molin, Robert Bissonnette, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 13, 2023
S2k-Leitlinie Diagnostik, Prävention und Therapie des Handekzems: S2k guideline diagnosis, prevention and therapy of hand eczemaAndrea Bauer, Richard Brans, Randolf Brehler, et al.
Journal Der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG|September 13, 2023
S2k guideline diagnosis, prevention, and therapy of hand eczemaAndrea Bauer, Richard Brans, Randolf Brehler, et al.
Contact Dermatitis|May 13, 2017
Current knowledge on biomarkers for contact sensitization and allergic contact dermatitisSjors A Koppes, Kristiane A Engebretsen, Tove Agner, et al.
Contact Dermatitis|July 1, 2016
A variant of the CXCL11 gene may influence susceptibility to contact allergy, particularly in polysensitized patientsGötz A Westphal, Hans-Peter Rihs, Antje Schaffranek, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|April 25, 2025
Consensus on core domains for hand eczema trials: Signs, symptoms, control and quality of lifeHenriette Rönsch, Karl Philipp Drewitz, Amber Reck Atwater, et al.
Pageof 7